Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02).

Humans Carcinoma, Non-Small-Cell Lung / drug therapy Lung Neoplasms / drug therapy Consolidation Chemotherapy Retrospective Studies Antineoplastic Agents, Immunological Neoplasm Staging Chemoradiotherapy Disease Progression
Chemoradiotherapy Durvalumab Stage III non-small-cell lung cancer Subsequent treatment

Journal

Cancer chemotherapy and pharmacology
ISSN: 1432-0843
Titre abrégé: Cancer Chemother Pharmacol
Pays: Germany
ID NLM: 7806519

Informations de publication

Date de publication:
07 2023
Historique:
received: 08 03 2023
accepted: 19 05 2023
medline: 14 6 2023
pubmed: 27 5 2023
entrez: 27 5 2023
Statut: ppublish

Résumé

For patients with locally advanced non-small-cell lung cancer (LA-NSCLC) that progressed after definitive chemoradiotherapy (CRT) and durvalumab consolidation therapy, no subsequent standard treatment exists. The type of treatment selected for each timing of disease progression and its efficacy have not been investigated. We retrospectively enrolled patients with LA-NSCLC or inoperable NSCLC that progressed after definitive CRT and durvalumab consolidation therapy at 15 Japanese institutions. Patients were classified into the following: Early Discontinuation group (disease progression within 6 months after durvalumab initiation), Late Discontinuation group (disease progression from 7 to 12 months after durvalumab initiation), and Accomplishment group (disease progression from 12 months after durvalumab initiation). Altogether, 127 patients were analyzed, including 50 (39.4%), 42 (33.1%) and 35 (27.5%) patients from the Early Discontinuation, Late Discontinuation, and Accomplishment groups, respectively. Subsequent treatments were Platinum plus immune checkpoint inhibitors (ICI) in 18 (14.2%), ICI in 7 (5.5%), Platinum in 59 (46.4%), Non-Platinum in 35 (27.6%), and tyrosine kinase inhibitor in 8 (6.3%) patients. In the Early Discontinuation, Late Discontinuation, and Accomplishment groups, 4 (8.0%), 7 (16.7%), and 7 (20.0%) patients were receiving Platinum plus ICI; 21 (42.0%), 22 (52.4%), and 16 (45.7%) were receiving Platinum, and 20 (40.0%), 8 (19.0%), and 7 (20.0%) were receiving Non-Platinum, respectively. No significant difference in progression-free survival was observed in the timing of disease progression. In patients with LA-NSCLC hat progressed after definitive CRT and durvalumab consolidation therapy, subsequent treatment may change depending on the timing of disease progression.

Identifiants

DOI: 10.1007/s00280-023-04547-2 PMID: 37243795
pubmed: 37243795
doi: 10.1007/s00280-023-04547-2
pii: 10.1007/s00280-023-04547-2
doi:

Substances chimiques

durvalumab 28X28X9OKV
Antineoplastic Agents, Immunological 0

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

29-37

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Marino P, Preatoni A, Cantoni A (1995) Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis. Cancer 76(4):593–601. https://doi.org/10.1002/1097-0142(19950815)76:4%3c593::aid-cncr2820760409%3e3.0.co;2-n
doi: 10.1002/1097-0142(19950815)76:4<593::aid-cncr2820760409>3.0.co;2-n pubmed: 8625152
Pritchard RS, Anthony SP (1996) Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis. Ann Intern Med 125(9):723–729. https://doi.org/10.7326/0003-4819-125-9-199611010-00003
doi: 10.7326/0003-4819-125-9-199611010-00003 pubmed: 8929005
Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, Yamanaka T, Bozonnat MC, Uitterhoeve A, Wang X, Stewart L, Arriagada R, Burdett S, Pignon JP (2010) Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 28(13):2181–2190. https://doi.org/10.1200/jco.2009.26.2543
doi: 10.1200/jco.2009.26.2543 pubmed: 20351327
Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, Vansteenkiste JF, Garassino MC, Hui R, Quantin X, Rimner A, Wu YL, Özgüroğlu M, Lee KH, Kato T, de Wit M, Kurata T, Reck M, Cho BC, Senan S, Naidoo J, Mann H, Newton M, Thiyagarajah P, Antonia SJ (2022) Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol 40(12):1301–1311. https://doi.org/10.1200/jco.21.01308
doi: 10.1200/jco.21.01308 pubmed: 35108059 pmcid: 9015199
Imai H, Kaira K, Mori K, Ono A, Akamatsu H, Taira T, Yoshino R, Kenmotsu H, Saitoh J, Harada H, Naito T, Murakami H, Tomizawa Y, Matsuura M, Saito R, Nakajima T, Yamada M, Takahashi T (2015) Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy. Springerplus 4:152. https://doi.org/10.1186/s40064-015-0929-3
doi: 10.1186/s40064-015-0929-3 pubmed: 25897409 pmcid: 4395619
Giaj Levra M, Cotte FE, Corre R, Calvet C, Gaudin AF, Penrod JR, Grumberg V, Jouaneton B, Jolivel R, Assie JB, Chouaid C (2020) Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: a national data base analysis. Lung Cancer 140:99–106. https://doi.org/10.1016/j.lungcan.2019.12.017
doi: 10.1016/j.lungcan.2019.12.017 pubmed: 31911324
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro CJ, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Özgüroğlu M (2018) Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 379(24):2342–2350. https://doi.org/10.1056/NEJMoa1809697
doi: 10.1056/NEJMoa1809697 pubmed: 30280658
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247. https://doi.org/10.1016/j.ejca.2008.10.026
doi: 10.1016/j.ejca.2008.10.026 pubmed: 19097774
Freites-Martinez A, Santana N, Arias-Santiago S, Viera A (2021) Using the common terminology criteria for adverse events (CTCAE—version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed) 112(1):90–92. https://doi.org/10.1016/j.ad.2019.05.009
doi: 10.1016/j.ad.2019.05.009 pubmed: 32891586
Giaccone G, Ferrati P, Donadio M, Testore F, Calciati A (1987) Reinduction chemotherapy in small cell lung cancer. Eur J Cancer Clin Oncol 23(11):1697–1699. https://doi.org/10.1016/0277-5379(87)90452-4
doi: 10.1016/0277-5379(87)90452-4 pubmed: 2828074
Wakuda K, Kenmotsu H, Naito T, Akamatsu H, Ono A, Shukuya T, Nakamura Y, Tsuya A, Murakami H, Takahashi T, Endo M, Nakajima T, Yamamoto N (2015) Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer. Am J Clin Oncol 38(1):28–32. https://doi.org/10.1097/COC.0b013e318286907b
doi: 10.1097/COC.0b013e318286907b pubmed: 23388567
Kim YH, Goto K, Yoh K, Niho S, Ohmatsu H, Kubota K, Saijo N, Nishiwaki Y (2008) Performance status and sensitivity to first-line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second-line chemotherapy. Cancer 113(9):2518–2523. https://doi.org/10.1002/cncr.23871
doi: 10.1002/cncr.23871 pubmed: 18780323
Schoenfeld AJ, Antonia SJ, Awad MM, Felip E, Gainor J, Gettinger SN, Hodi FS, Johnson ML, Leighl NB, Lovly CM, Mok T, Perol M, Reck M, Solomon B, Soria JC, Tan DSW, Peters S, Hellmann MD (2021) Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer. Ann Oncol 32(12):1597–1607. https://doi.org/10.1016/j.annonc.2021.08.2151
doi: 10.1016/j.annonc.2021.08.2151 pubmed: 34487855

Auteurs

Tsukasa Hasegawa (T)

Division of Respiratory Disease, Department of Internal Medicine, The Jikei University Daisan Hospital, Tokyo, Japan.

Ryo Ariyasu (R)

Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan. ryo.ariyasu@jfcr.or.jp.
ORCID: 0000-0003-4393-9176

Hisashi Tanaka (H)

Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Ryota Saito (R)

Department of Respiratory Medicine, Tohoku University Hospital, Sendai, Japan.

Yosuke Kawashima (Y)

Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.

Atsushi Horiike (A)

Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.

Toshio Sakatani (T)

Division of Respiratory, NTT Medical Center, Tokyo, Japan.

Takehiro Tozuka (T)

Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.

Jun Shiihara (J)

Department of Pulmonary Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.

Masafumi Saiki (M)

Department of Respiratory Medicine, Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan.

Yuichi Tambo (Y)

Department of Respiratory Medicine, Kanazawa University, Kanazawa, Japan.

Tomoaki Sonoda (T)

Third Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.

Akito Miyazaki (A)

Department of Thoracic Oncology, National Hospital Organization Osaka Toneyama Medical Center, Osaka, Japan.

Shinya Uematsu (S)

Department of Respiratory Medicine, Osaka Red Cross Hospital, Osaka, Japan.

Yuko Tsuchiya-Kawano (Y)

Department of Respiratory Medicine, Kitakyushu Municipal Medical Center, Kitakyushu, Japan.

Noriko Yanagitani (N)

Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

Makoto Nishino (M)

Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Subsequent treatment for locally advanced...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Tumeurs des bronches › Carcinome bronchogénique › Carcinome pulmonaire non à petites cellules › Subsequent treatment for locally advanced...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Subsequent treatment for locally advanced...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Chimiothérapie de consolidation › Subsequent treatment for locally advanced...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Subsequent treatment for locally advanced...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Antinéoplasiques immunologiques › Subsequent treatment for locally advanced...
questionsmedicales.fr › Diagnostic › Pronostic › Stadification tumorale › Subsequent treatment for locally advanced...
questionsmedicales.fr › Thérapeutique › Radiothérapie › Chimioradiothérapie › Subsequent treatment for locally advanced...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Évolution de la maladie › Subsequent treatment for locally advanced...